Ulf Darsow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulf Darsow has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Tilo Biedermann
Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
6 shared publications T. Biedermann
Department of Dermatology and Allergy Biederstein, TUM School of Medicine and Health Technical University of Munich Munich Germany
5 shared publications- Johannes Ring
Department of Dermatology and Allergy Technical University of Munich Munich Germany
4 shared publications - Ulrike Raap
Department of Dermatology and Allergy Klinikum Oldenburg Oldenburg Germany
4 shared publications - Bernadette Eberlein
Department of Dermatology and Allergy School of Medicine Technical University of Munich Munich Germany
3 shared publications C. Kugler
2 shared publications
Latest Publications
- Open Access
Comparative Assessment of the Allergenicity of Hyaluronidases from Polistes dominula (Pol d 2), Vespula vulgaris (Ves v 2), and Apis mellifera Venom (Api m 2)
Sensitization to cross-reactive allergens complicates identifying the culprit insect in Hymenoptera venom allergy via diagnostic tests. This study evaluates sensitization to hyaluronidases (Api m 2 from honey bee (Apis mellifera) venom, HBV; Pol d 2 from European paper wasp (Polistes dominula) venom, PDV; and Ves v 2.0101 and Ves v 2.0201 from yellow jacket (Vespula vulgaris) venom, YJV) and their cross-reactivity in allergic patients from Italy, Spain, and Germany using ImmunoCAPs, ELISA, and basophil activation tests. Sensitization rates were 45% for Api m 2 in HBV-allergic subjects, 25% for Pol d 2 in PDV-allergic individuals, and 20% and 10% for Ves v 2.0201 and Ves v 2.0101 in YJV-allergic patients, respectively. Patients primarily sensitized to Api m 2 showed minimal cross-reactivity to vespid hyaluronidases, whereas those primarily sensitized to Pol d 2 or Ves v 2.0201 exhibited IgE reactivity to Api m 2. Neither Pol d 2 nor Ves v 2.0201 triggered basophil activation. Cross-reactivity of Api m 2, Pol d 2, and Ves v 2.0201 depends on the primary sensitizing venom. Sensitization to Pol d 2 and Ves v 2.0201 remains below 25%, yet these patients may exhibit cross-reactivity to Api m 2. Conversely, HBV-allergic patients sensitized to Api m 2 show minimal reactivity to Pol d 2 or Ves v 2.0201.
Open AccessComparative Assessment of the Allergenicity of Hyaluronidases from Polistes dominula (Pol d 2), Vespula vulgaris (Ves v 2), and Apis mellifera Venom (Api m 2)
Sensitization to cross-reactive allergens complicates identifying the culprit insect in Hymenoptera venom allergy via diagnostic tests. This study evaluates sensitization to hyaluronidases (Api m 2 from honey bee (Apis mellifera) venom, HBV; Pol d 2 from European paper wasp (Polistes dominula) venom, PDV; and Ves v 2.0101 and Ves v 2.0201 from yellow jacket (Vespula vulgaris) venom, YJV) and their cross-reactivity in allergic patients from Italy, Spain, and Germany using ImmunoCAPs, ELISA, and basophil activation tests. Sensitization rates were 45% for Api m 2 in HBV-allergic subjects, 25% for Pol d 2 in PDV-allergic individuals, and 20% and 10% for Ves v 2.0201 and Ves v 2.0101 in YJV-allergic patients, respectively. Patients primarily sensitized to Api m 2 showed minimal cross-reactivity to vespid hyaluronidases, whereas those primarily sensitized to Pol d 2 or Ves v 2.0201 exhibited IgE reactivity to Api m 2. Neither Pol d 2 nor Ves v 2.0201 triggered basophil activation. Cross-reactivity of Api m 2, Pol d 2, and Ves v 2.0201 depends on the primary sensitizing venom. Sensitization to Pol d 2 and Ves v 2.0201 remains below 25%, yet these patients may exhibit cross-reactivity to Api m 2. Conversely, HBV-allergic patients sensitized to Api m 2 show minimal reactivity to Pol d 2 or Ves v 2.0201.
- Open Access
Algorithms in allergy: An algorithm for alpha‐Gal syndrome diagnosis and treatment, 2024 update
- 28 August 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (12) , 3724-3731.e11
Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance
- 28 August 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (12) , 3724-3731.e11
Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance
- 1 December 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 45 (12) , 894-907
Wir stellen uns vor: Allergiezentrum der TU München
- 1 December 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 45 (12) , 894-907
Wir stellen uns vor: Allergiezentrum der TU München
- Open Access
A Pilot Study of a Mindfulness-Based Stress Reduction Programme in Patients Suffering from Atopic Dermatitis
Introduction: Patients with atopic dermatitis (AD) have several potential stressors including the symptoms of the disease itself, the stigmatization due to their appearance, and emotional and psychological strain. Psychological factors and stress can trigger and exacerbate the symptoms of skin diseases and there is evidence that stress has a relevant clinical effect on the function of skin cells in vivo. Our objective was to evaluate in a pilot study the feasibility, acceptance, and effectiveness of a Mindfulness-Based Stress Reduction (MBSR) programme in AD patients in a clinical setting. Methods: 10 patients took part in an 8-week MBSR programme, which included, e.g., mindful and conscious awareness of the body and bodywork, and seated meditation. We assessed sociodemographics and disease related variables with standardized measures at predefined time points including Score of Atopic Dermatitis, Patient Oriented Eczema Measure, Dermatology Life Quality Index, Perceived Stress Questionnaire, Freiburg Mindfulness Inventory (FMI), and others. Participants also gave qualitative feedback regarding the effects of the intervention. Results: The mean age was 53.10 years (SD = 15.04), seven patients were female, and disease duration was 36.6 years (SD = 25.5). Calculating pre-post effect sizes (Cohen’s d), the FMI indicated significant improvement in the “presence” and “acceptance” subscales. There was also tendency for less stress. This was confirmed by the qualitative statements of the participants. Conclusions: The MBSR programme is feasible and acceptable for AD patients. Considering the long disease history and the severity of disease burden, the effects of this intervention seem promising as an adjunct to conventional treatments for patients with AD.
Open AccessA Pilot Study of a Mindfulness-Based Stress Reduction Programme in Patients Suffering from Atopic Dermatitis
Introduction: Patients with atopic dermatitis (AD) have several potential stressors including the symptoms of the disease itself, the stigmatization due to their appearance, and emotional and psychological strain. Psychological factors and stress can trigger and exacerbate the symptoms of skin diseases and there is evidence that stress has a relevant clinical effect on the function of skin cells in vivo. Our objective was to evaluate in a pilot study the feasibility, acceptance, and effectiveness of a Mindfulness-Based Stress Reduction (MBSR) programme in AD patients in a clinical setting. Methods: 10 patients took part in an 8-week MBSR programme, which included, e.g., mindful and conscious awareness of the body and bodywork, and seated meditation. We assessed sociodemographics and disease related variables with standardized measures at predefined time points including Score of Atopic Dermatitis, Patient Oriented Eczema Measure, Dermatology Life Quality Index, Perceived Stress Questionnaire, Freiburg Mindfulness Inventory (FMI), and others. Participants also gave qualitative feedback regarding the effects of the intervention. Results: The mean age was 53.10 years (SD = 15.04), seven patients were female, and disease duration was 36.6 years (SD = 25.5). Calculating pre-post effect sizes (Cohen’s d), the FMI indicated significant improvement in the “presence” and “acceptance” subscales. There was also tendency for less stress. This was confirmed by the qualitative statements of the participants. Conclusions: The MBSR programme is feasible and acceptable for AD patients. Considering the long disease history and the severity of disease burden, the effects of this intervention seem promising as an adjunct to conventional treatments for patients with AD.
- Open Access
Characterization of New Allergens from the Venom of the European Paper Wasp Polistes dominula
Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
Open AccessCharacterization of New Allergens from the Venom of the European Paper Wasp Polistes dominula
Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
- 1 April 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 44 (04) , 288-296
α-Gal-Syndrom – nicht nur eine Fleischallergie
- 1 April 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 44 (04) , 288-296
α-Gal-Syndrom – nicht nur eine Fleischallergie
- 13 October 2020
- Published by Springer Nature
- p. 619-630
Atopy Patch Testing with Aeroallergens and Food Proteins
- 13 October 2020
- Published by Springer Nature
- p. 619-630
Atopy Patch Testing with Aeroallergens and Food Proteins
- 21 December 2019
- Published by Springer Nature
- p. 1-12
Atopy Patch Testing with Aeroallergens and Food Proteins
- 21 December 2019
- Published by Springer Nature
- p. 1-12
Atopy Patch Testing with Aeroallergens and Food Proteins
- 1 July 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 42 (07) , 305-308
Perioperative Anaphylaxie durch Patentblau V: schwierige allergologische Diagnosestellung
- 1 July 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 42 (07) , 305-308
Perioperative Anaphylaxie durch Patentblau V: schwierige allergologische Diagnosestellung